Your Messages Inbox
Your Article Summary
See Latest ArticlesMylan Reports That the FDA Determined That All Accusations Were Unfounded
Mylan, 07/29/09
Mylan Inc. reported that in addition to the press release it issued on Sunday, the company proactively and as a courtesy had contacted the U.S. Food and Drug Administration (FDA) over the weekend to bring to its attention a recent news article. As a result, the FDA visited the company's Morgantown, W.Va., manufacturing facility Monday morning and has determined that the baseless accusations in the article were unfounded. The FDA noted there was no evidence of any data deletion. All data was reviewed and was present and accounted for; the Agency agreed that this was a minor Standard Operating Procedures (SOP) deviation that existed, was fully investigated, and all corrective actions were fully implemented by Mylan.
Today in Regulatory Issues...keeping you current
Receive free subspecialty "5-minute updates" via email
The Unintended Consequences of Clinical Trials Regulations
PLoS Medicine, 12/04/09
Mandatory Disclosure of Pharmaceutical Industry-Funded Events for Health Professionals
PLoS Medicine, 12/02/09
FDA drug approval intervals from 1997 to 2006: analysis and comparison during information technology implementation
International Journal of Electronic Healthcare , 12/01/09
Article Search
Sponsor